Tag Archives: EUnetHTA

HTAs Impact on Biosimilars in Europe

Cuts in healthcare costs due to post-recession austerity programs mean favorable Health Technology Assessments (HTAs) are becoming crucial to the successful market launch of pharmaceuticals in Europe. HTAs backing reimbursement can be vital for new innovative medicines and also for biosimilars. EUnetHTA has been stepping up its efforts to achieve more consistency in the methodology […]
Posted in Europe, Regulatory | Also tagged , , , , | Leave a comment

Europe: EMA and EUnetHTA Agree Three-Year Work Plan

By Leela Barham. Collaboration seems to be ‘in’ thing and it’s set to continue in Europe with the European Medicines Agency (EMA) and EUnetHTA agreeing a three-year joint work plan.
Posted in Europe, Global, Guest Blog, healthcare, Strategy | Also tagged , , , , | Leave a comment

Europe: Into the HTA Fray

Reflector finds some surprising common ground in what should be two very different HTA reports. Just like with buses, you wait for ages for an international review of health technology assessment to come along, then two turn up at once.
Posted in Europe, Global, Guest Blog, healthcare, pricing, Regulatory | Also tagged , , , , | Leave a comment
  • Categories

  • Meta